TOPLINE:

In a retrospective study, Hispanic patients developed a second cutaneous squamous cell carcinoma (cSCC) less frequently and later than non-Hispanic patients.

METHODOLOGY:

• Researchers evaluated 65 Hispanic patients (mean age, 63.7 years at diagnosis; 43.1% women; 53.8% White, 26.2% other race; 15% race unknown) who were diagnosed with cSCC for the first time between 2013 and 2020.
• The analysis included 111 non-Hispanic patients (98.2% White) matched by age at first diagnosis (within 5 years), sex, smoking status, and year of first biopsy (within 2 years).
• The primary outcome was new primary tumors occurring ≥ 2 months after the first tumor and the time between first and second cSCC.

TAKEAWAY:

• A second cSCC developed in 24.6% of Hispanic patients vs 55.0% of non-Hispanic patients.
• The median time to a second cSCC was longer in Hispanic patients than in non-Hispanic patients (6.68 vs 3.76 years; P = .036).
• Hispanic patients had a 46% lower risk for a second cSCC than non-Hispanic patients (hazard ratio [HR], 0.54; P = .042).
• Immunosuppressed Hispanic patients showed a significantly higher risk for a second cSCC than nonimmunosuppressed Hispanic patients (HR, 4.62; P = .008), whereas no significant difference was observed in non-Hispanics by immunosuppression status.

IN PRACTICE:

“Our findings suggest that Hispanic patients develop a second cSCC less frequently and later than non-Hispanics,” the authors wrote. “Surveillance remains essential for both groups, with particular vigilance warranted for immunosuppressed Hispanic patients,” they added.

SOURCE:

The study was led by Kelly E. Owens, MD, Department of Dermatology, Duke University School of Medicine, Durham, North Carolina, and was published online on January 6 in JAAD International.

LIMITATIONS:

The study’s limitations included its retrospective nature, single-institution design, small sample size, and potential missing data from outside diagnoses. The matching process could have resulted in a non-Hispanic cohort that is not fully representative of typical study populations.

DISCLOSURES:

The study was funded by the Department of Dermatology at Duke University School of Medicine and the National Center for Advancing Translational Sciences, National Institutes of Health. The authors reported having no conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.